Vaccination strategy

Patent metadata

Field	Value
Publication number	US-10195267-B2
Application number	US-201414769987-A
Country	US
Kind code	B2
Filing date	Feb 25, 2014
Priority date	Feb 25, 2013
Publication date	Feb 5, 2019
Grant date	Feb 5, 2019

Abstract

In a first aspect, the present invention relates to the use of a TLR 9 agonist and/or a TLR 4 agonist in a prophylactic or therapeutic vaccine. According to the present vaccination strategy, the TLR 9 agonist and/or TLR 4 agonist is adapted or designed for use as a multiplying jump agent to enhance numbers and functionality of CD8 T cells in a prime-jump vaccination strategy for jump T cell expansion. In particular, the TLR 9 agonist and/or TLR 4 agonist is used as a component to be administered after priming of the individual to be vaccinated. The vaccination strategy is particularly useful against acute and chronic infections with intracellular pathogens or for anti-tumor vaccination. In another aspect, the present invention relates to a kit of part containing a prime agent and a multiplying jump agent according to the present invention.

First claim

The invention claimed is:

1. A method for expansion of effector CD8 T cells comprising the steps of:
administering a priming agent,
separately administering a TLR9 agonist at least 6 days after the administration of the priming agent; and
wherein the TLR9 agonist is administered as a multiplying jump agent enhancing the number and functionality of CD8 T cells.

2. The method for expansion of effector CD8 T cells according to claim 1 wherein the TLR9 agonist is administered with a time range of 10 to 20 days after administration of the priming agent.

3. The method for expansion of effector CD8 T cells according claim 1 for vaccination against infection with an intracellular pathogen or cancer.

4. The method for expansion of effector CD8 T cells against infection with an intracellular pathogen according to claim 3 wherein the intracellular pathogen is a viral pathogen, an intracellular bacterial pathogen or an intracellular parasite.

5. The method for expansion of effector CD8 T cells according to claim 1 wherein the vaccination is against a chronic or acute infection.

6. The method for expansion of effector CD8 T cells against a chronic or acute infection according to claim 5 when the chronic or acute infection is a chronic or acute viral infection.

7. The method for expansion of effector CD8 T cells according claim 1 wherein the TLR9 agonist is selected from CpG oligonucleotide, in particular, a CpG oligodeoxynucleotide.

8. The method for expansion of effector CD8 T cells according to claim 1 wherein administration of the TLR9 agonist is intravenously or to a vascularized area.

9. The method for expansion of effector CD8 T cells according to claim 1 wherein the TLR9 agonist is administered in a composition in which the TLR9 agonist is the only active ingredients.

10. The method for expansion of effector CD8 T cells according to claim 9 wherein the priming agent is an antigenic compound stemming from an intracellular pathogen to be vaccinated against allowing secondary CD8 T cell expansion, in particular, expansion of effector CD8 T cells.

Assignees

• Univ Bonn Rheinische Friedrich Wilhelms
• Univ Muenchen Tech
• Helmholtz Zentrum Muenchen Deutshes Forschungszentrum Fuer Gesundheit Und Umwelt Gmbh
• Klinikum Rechts Der Isar Der Technischen Univ Muenchen
• Tech Univ Muenchen
• Helmholtz Zentrum Muenchen—Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt

Inventors

• Knolle Percy
• Huang Li-Rung
• Heikenwälder Mathias
• Protzer Ulrike

Classifications

• A61K2039/525

  Virus · CPC title

• A61K39/292 Primary

  Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen · CPC title

• A61K39/39 Primary

  characterised by the immunostimulating additives, e.g. chemical adjuvants · CPC title

• C12N2730/10134

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• C12N2730/10171

  Demonstrated in vivo effect · CPC title